Immunic, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDImmunic, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 95), indicating clear outperformance against the broad market. Earnings growth of 57% provides fundamental context to the price action. Investors should exercise caution due to high volatility (122% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $14.23 | +7.94% | ABOVE |
| 50 SMA | $12.99 | +18.24% | ABOVE |
| 100 SMA | $11.95 | +28.54% | ABOVE |
| 150 SMA | $10.08 | +52.32% | ABOVE |
| 200 SMA | $9.60 | +60.01% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is IMUX in an uptrend right now?
IMUX has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, IMUX is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is IMUX overbought or oversold?
IMUX's RSI (14) is 58. The stock is in neutral territory, neither overbought nor oversold.
Is IMUX outperforming the market?
IMUX has a Relative Strength (RS) Rating of 95 out of 99. Yes, IMUX is a market leader, outperforming 95% of all stocks over the past 12 months.
Where is IMUX in its 52-week range?
IMUX is trading at $15.36, which is 97% of its 52-week high ($15.78) and 97% above its 52-week low ($0.67).
How volatile is IMUX?
IMUX has a Beta of 1.61 and 52-week volatility of 122%. It's more volatile than the S&P 500 - expect bigger swings.